Oral Pentoxifylline Combined with Pentavalent Antimony: A Randomized Trial for Mucosal Leishmaniasis | Zendy

Pablo Machado | Zendy; Hélio A. Lessa | Zendy; Marcus Miranda Lessa | Zendy; Luiz Henrique Guimarães | Zendy; Heejung Bang | Zendy; John L. Ho | Zendy; Edgar M. Carvalho | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Pentoxifylline Combined with Pentavalent Antimony: A Randomized Trial for Mucosal Leishmaniasis

Author(s) -

Pablo Machado,

Hélio A. Lessa,

Marcus Miranda Lessa,

Luiz Henrique Guimarães,

Heejung Bang,

John L. Ho,

Edgar M. Carvalho

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/511643

Subject(s) - pentoxifylline , medicine , placebo , gastroenterology , refractory (planetary science) , randomized controlled trial , cutaneous leishmaniasis , chemotherapy , surgery , clinical trial , leishmaniasis , immunology , pathology , physics , alternative medicine , astrobiology

Mucosal leishmaniasis is associated with intense tissue damage and high tumor necrosis factor-alpha production. Therapeutic failure occurs in up to 42% of cases; patients who experience treatment failure will require >1 pentavalent antimony (Sb(v)) course or alternative drugs to achieve a cure. We previously showed that an inhibitor of tumor necrosis factor-alpha (pentoxifylline) combined with Sb(v) cured 90% patients refractory to monotherapy with Sb(v).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research